We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mind Medicine MindMed Inc | NASDAQ:MNMD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.3204 | -4.25% | 7.2196 | 7.07 | 8.00 | 7.88 | 7.07 | 7.65 | 2,065,573 | 05:00:03 |
From Dec 2024 to Jan 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.
Details of the presentations are as follows:
Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder Format: Poster Presenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed
Title: Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization study Format: Poster Presenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed
Posters are available on MindMed’s Company website.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
This press release is not sanctioned by ACNP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211736280/en/
For Media: media@mindmed.co For Investors: ir@mindmed.co For Medical Affairs: medaffairs@mindmed.co
1 Year Mind Medicine MindMed Chart |
1 Month Mind Medicine MindMed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
